Two Major Independent Proxy Advisory Firms Recommend Nabi Biopharmaceuticals Stockholders Support Amended Transaction With Biota Holdings Limited at October 22nd Reconvened Special Meeting

ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nadsaq:NABI) ("Nabi") today announced that the two major independent proxy advisory firms, Institutional Shareholder Services ("ISS") and Glass Lewis, have recommended that Nabi stockholders support the recently amended transaction agreement with Biota Holdings Limited (ASX:BTA.AX) ("Biota") pursuant to which Nabi would acquire all of the outstanding shares of Biota in exchange for shares of Nabi common stock (the "Transaction"). ISS and Glass Lewis are the leading independent proxy advisory firms and their voting analyses and recommendations are relied upon by hundreds of institutional investment funds, mutual funds and fiduciaries throughout the world.